TrialNeuro-oncology2013

Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.

Jerrold L Boxerman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.